Melfalan Teva (Melphalan Hydrochloride)

Melphalan hydrochloride is an alkylating agent that forms covalent bonds with DNA, primarily at the N7 position of guanine. This creates cross‑links that block DNA replication and transcription, leading to apoptosis of rapidly dividing tumor cells.

The dose of Melfalan Teva is individualized by the prescribing oncologist based on the specific cancer type, treatment protocol, patient weight, renal function and other clinical factors. No standard dose is provided here.

Melphalan is classified as teratogenic and can cause fetal harm. It is contraindicated in pregnancy, and women of child‑bearing potential should use effective contraception. Safety during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Both melphalan and cyclophosphamide belong to the nitrogen‑mustard alkylating class, but melphalan is more lipophilic and often used for hematologic malignancies like multiple myeloma, whereas cyclophosphamide has broader use in solid‑tumor protocols. Their toxicity profiles differ, with melphalan showing higher rates of mucosal toxicity.

Melfalan Teva should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

Melfalan Teva is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The infusion rate and duration are determined by the treating physician and are usually based on institutional protocols.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, and pulmonary toxicity such as interstitial pneumonitis. Patients should be monitored closely for signs of infection, respiratory symptoms and abnormal blood counts.

Melfalan Teva is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in pregnant women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with significant renal or pulmonary impairment.